StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Price Performance
Shares of NASDAQ:AKTX opened at $1.19 on Wednesday. Akari Therapeutics has a 52 week low of $1.08 and a 52 week high of $5.50. The company’s 50 day moving average is $1.77 and its two-hundred day moving average is $2.59.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Akari Therapeutics stock. Omnia Family Wealth LLC lifted its stake in Akari Therapeutics, Plc (NASDAQ:AKTX – Free Report) by 48.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,628 shares of the biopharmaceutical company’s stock after buying an additional 28,511 shares during the period. Omnia Family Wealth LLC owned approximately 1.55% of Akari Therapeutics worth $273,000 at the end of the most recent quarter. 5.06% of the stock is currently owned by hedge funds and other institutional investors.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Further Reading
- Five stocks we like better than Akari Therapeutics
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 4/22 – 4/26
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Stocks Leading the U.S. Agriculture Comeback
- Investing in Travel Stocks Benefits
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
